ME Therapeutics Holdings, Inc. provides biotechnology and pharmaceutical services. It engages in research and development of cancer fighting drugs in the field of immuno-oncology (IO). ME Therapeutics Holdings develops drug candidates that can increase the efficacy of current IO drugs by targeting suppressive myeloid cells which are known to hinder the effectiveness of current IO treatments. The company was founded on November 9, 2021 and is headquartered in Vancouver, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company